Patients with gastroparesis often suffer with chronic gastrointestinal symptoms that are not adequately treated due to both a lack of understanding of the underlying pathophysiology and lack of effective treatments. The participation of Temple University in the NIH/NIDDK Gastroparesis Clinical Research Consortium and the proposed studies will help achieve the broad, long term objectives of improving the diagnosis and treatment of patients with gastroparesis. The PI and Temple University are exceptionally well qualified to continue to be one of the clinical centers in this consortium. Temple University has clinical expertise and an active research program in the evaluation and treatment of patients with gastroparesis.
The aims for this renewal of the Gastroparesis Consortium are threefold. First, to complete the ongoing and approved studies initiated by the GpCRC. These studies include NORIG: a randomized trial of nortriptyline vs. placebo for idiopathic gastroparesis;GLUMIT-DG: a pilot study of safety, feasibility and potential efficacy of continuous glucose monitoring and insulin pump therapy in diabetic gastroparesis;APRON: a randomized trial of aprepitant vs. placebo for the relief of nausea in patients with chronic nausea and vomiting of presumed gastric origin;PBG: pathological basis of gastroparesis, a tissue study from full thickness gastric biopsies. Second, to maintain and expand the Gastroparesis Registry.
Our aim i s to have at least four years of follow-up on patients and with up to nine years for some patients. This will require maintenance of the Registry and continued periodic follow-up visits over the next five years. In addition, we propose recruitment of new patients during continuation of the Gastroparesis Consortium with refinements to existing questionnaires and pathophysiologic measures, as well as new ones. This will allow us to answer questions related to the pathogenesis, severity grading, complications, treatment responses, and clinical outcomes in patients with gastroparesis. Third, to conduct new multicenter studies of gastroparesis investigating the etiology, pathogenesis, diagnosis, and treatment. The PI with his collaborators at Temple University propose a multicenter study aimed at improving the diagnosis of gastric motility disorders. The overall purpose of this project is to develop a single more comprehensive noninvasive test which evaluates several components of gastric motility and, thus, may improve the correlation between dyspeptic symptoms and gastric dysmotility. This will ultimately enable physicians to better target therapy to the underlying gastric pathophysiologic abnormality in patients with gastroparesis.
Patients with gastroparesis often suffer with chronic gastrointestinal symptoms that are not adequately treated due to both a lack of understanding of the underlying causes and lack of effective treatments. The NIH Gastroparesis Clinical Research Consortium and the studies undertaken will help improve the understanding of gastroparesis and the diagnosis and treatment of patients with gastroparesis.
|Bernard, C E; Gibbons, S J; Mann, I S et al. (2014) Association of low numbers of CD206-positive cells with loss of ICC in the gastric body of patients with diabetic gastroparesis. Neurogastroenterol Motil 26:1275-84|
|Parkman, Henry P; Yates, Katherine; Hasler, William L et al. (2013) Cholecystectomy and clinical presentations of gastroparesis. Dig Dis Sci 58:1062-73|
|Camilleri, Michael; Parkman, Henry P; Shafi, Mehnaz A et al. (2013) Clinical guideline: management of gastroparesis. Am J Gastroenterol 108:18-37; quiz 38|
|Hasler, W L; Wilson, L A; Parkman, H P et al. (2013) Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting. Neurogastroenterol Motil 25:427-38, e300-1|
|Parkman, Henry P; Van Natta, Mark L; Abell, Thomas L et al. (2013) Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA 310:2640-9|
|Iorio, Raffaele; Lucchinetti, Claudia F; Lennon, Vanda A et al. (2013) Intractable nausea and vomiting from autoantibodies against a brain water channel. Clin Gastroenterol Hepatol 11:240-5|
|Grover, M; Bernard, C E; Pasricha, P J et al. (2012) Clinical-histological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. Neurogastroenterol Motil 24:531-9, e249|
|Hasler, William L; Wilson, Laura A; Parkman, Henry P et al. (2011) Bloating in gastroparesis: severity, impact, and associated factors. Am J Gastroenterol 106:1492-502|
|Pasricha, Pankaj J; Colvin, Ryan; Yates, Katherine et al. (2011) Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol 9:567-76.e1-4|
|Parkman, Henry P; Yates, Katherine P; Hasler, William L et al. (2011) Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis. Gastroenterology 141:486-98, 498.e1-7|
Showing the most recent 10 out of 14 publications